CpG methylation in cell-free Epstein-Barr virus DNA in patients with EBV-Hodgkin lymphoma
Open Access
- 28 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (8), 1624-1627
- https://doi.org/10.1182/bloodadvances.2020001511
Abstract
Epstein-Barr virus (EBV) is associated with a variety of tumors and nonmalignant conditions. Latent EBV genomes in cells, including tumor cells, are often CpG methylated, whereas virion DNA is not CpG methylated. We demonstrate that methyl CpG binding magnetic beads can be used to fractionate among sources of EBV DNA (DNA extracted from laboratory-purified virions vs DNA extracted from latently infected cell lines). We then applied the technique to plasma specimens and showed that this technique can distinguish EBV DNA from patients with EBV-associated tumors (nasopharyngeal carcinoma, Hodgkin lymphoma) and viral DNA from patients without EBV-associated tumors, including immunocompromised patients and patients with EBV(-) Hodgkin lymphoma.This publication has 21 references indexed in Scilit:
- The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesBlood, 2016
- Role of epigenetics in EBV regulation and pathogenesisFuture Microbiology, 2014
- Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinomaAnnals of Oncology, 2014
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trialBlood, 2013
- CpG-Methylation Regulates a Class of Epstein-Barr Virus PromotersPLoS Pathogens, 2010
- Prevalence and relevance of EBV latency in nasopharyngeal carcinoma in IsraelJournal of Clinical Pathology, 2004
- Guidelines for Interpreting EBER In Situ Hybridization and LMP1 Immunohistochemical Tests for Detecting Epstein-Barr Virus in Hodgkin LymphomaAmerican Journal of Clinical Pathology, 2002
- Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.2000
- Methylation Status of the Epstein-Barr Virus Major Latent Promoter C in Iatrogenic B Cell Lymphoproliferative Disease: Application of PCR-Based AnalysisThe American Journal of Pathology, 1999
- Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue.1998